FY2024 EPS Estimates for Xencor Raised by Leerink Partnrs

Xencor, Inc. (NASDAQ:XNCR) – Equities research analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for Xencor in a research note issued on Thursday, November 7th. Leerink Partnrs analyst J. Chang now forecasts that the biopharmaceutical company will post earnings per share of ($3.96) for the year, up from their previous forecast of ($4.36). The consensus estimate for Xencor’s current full-year earnings is ($3.91) per share. Leerink Partnrs also issued estimates for Xencor’s Q4 2024 earnings at ($1.07) EPS and FY2025 earnings at ($3.40) EPS.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $10.70 million for the quarter, compared to analyst estimates of $14.59 million. During the same quarter last year, the firm posted ($0.40) EPS. The firm’s revenue for the quarter was down 81.9% on a year-over-year basis.

A number of other analysts also recently commented on the stock. JPMorgan Chase & Co. increased their price objective on shares of Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Wedbush reaffirmed an “outperform” rating and issued a $38.00 price target on shares of Xencor in a report on Thursday, November 7th. Royal Bank of Canada boosted their price objective on Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Thursday, September 26th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $34.00 target price (up from $32.00) on shares of Xencor in a research note on Friday, November 8th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Xencor currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.75.

Xencor Price Performance

Shares of NASDAQ XNCR opened at $23.71 on Monday. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of -7.41 and a beta of 0.66. Xencor has a 52 week low of $15.31 and a 52 week high of $26.84. The firm has a 50-day simple moving average of $20.70 and a 200-day simple moving average of $20.34. The company has a quick ratio of 6.92, a current ratio of 6.23 and a debt-to-equity ratio of 0.01.

Hedge Funds Weigh In On Xencor

Several large investors have recently modified their holdings of XNCR. Darwin Global Management Ltd. acquired a new stake in shares of Xencor during the 1st quarter worth about $24,557,000. Logos Global Management LP boosted its stake in Xencor by 130.8% during the second quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock worth $28,395,000 after buying an additional 850,000 shares during the period. Point72 Asset Management L.P. increased its position in shares of Xencor by 52.9% during the second quarter. Point72 Asset Management L.P. now owns 1,261,789 shares of the biopharmaceutical company’s stock valued at $23,886,000 after acquiring an additional 436,389 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Xencor by 9.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock valued at $84,530,000 after acquiring an additional 335,881 shares during the period. Finally, Baker BROS. Advisors LP lifted its holdings in shares of Xencor by 122.2% in the 1st quarter. Baker BROS. Advisors LP now owns 545,431 shares of the biopharmaceutical company’s stock worth $12,070,000 after acquiring an additional 300,000 shares during the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.